A Multicenter Open label Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (MK3475-587)

Brief description of study

The purpose of this extension study is to continue to collect long term information on the safety of the study drug, pembrolizumab or pembrolizumab-based combinations, that you received or are receiving as part of the protocol you are currently enrolled in. This study is also being done to see how well the pembrolizumab or pembrolizumab-based combinations work and how your body reacts to the drug (or drugs) long term. The pharmaceutical company that is paying for this study is Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.).

Clinical Study Identifier: s18-01907
ClinicalTrials.gov Identifier: NCT03486873
Principal Investigator: Janice Mehnert.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.